Published in Oncoimmunology on February 18, 2016
Trial watch: Dendritic cell-based anticancer immunotherapy. Oncoimmunology (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
The Ki-67 protein: from the known and the unknown. J Cell Physiol (2000) 16.48
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
The B7 family revisited. Annu Rev Immunol (2005) 13.51
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
CTLA-4 can function as a negative regulator of T cell activation. Immunity (1994) 9.80
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med (1988) 8.90
Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat Immunol (2005) 8.27
Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science (2003) 7.75
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature (1999) 5.76
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res (2007) 5.51
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol (2015) 5.49
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
The emerging role of CTLA-4 as an immune attenuator. Immunity (1997) 5.35
Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol (2001) 4.99
Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol (2009) 4.69
Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol (2012) 4.44
CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A (2008) 3.04
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 3.03
T-bet is required for optimal proinflammatory CD4+ T-cell trafficking. Blood (2005) 2.95
Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89
The chemokine superfamily revisited. Immunity (2012) 2.83
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res (2010) 2.73
CXCR3 in T cell function. Exp Cell Res (2011) 2.54
Stepwise differentiation of CD4 memory T cells defined by expression of CCR7 and CD27. J Immunol (2005) 2.01
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol (2010) 1.98
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol (2013) 1.65
The who's who of T-cell differentiation: human memory T-cell subsets. Eur J Immunol (2013) 1.63
ICOS controls the pool size of effector-memory and regulatory T cells. J Immunol (2008) 1.62
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol (2014) 1.58
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med (2008) 1.56
Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin Cancer Res (2009) 1.49
CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res (2004) 1.43
CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res (2011) 1.42
Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev (2014) 1.39
T-bet and eomesodermin are required for T cell-mediated antitumor immune responses. J Immunol (2010) 1.36
Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res (2013) 1.29
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother (2010) 1.24
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother (2014) 1.23
On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci Transl Med (2015) 1.14
PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget (2015) 1.02
Immune responses to cancer: are they potential biomarkers of prognosis? Front Oncol (2013) 1.01
CXC chemokine ligand 9/monokine induced by IFN-gamma production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors. J Immunol (2007) 1.00
Tumor-infiltrating lymphocytes in melanoma. Curr Oncol Rep (2012) 0.97
CD152 (CTLA-4) regulates effector functions of CD8+ T lymphocytes by repressing Eomesodermin. Eur J Immunol (2009) 0.95
T-Bet and Eomes Regulate the Balance between the Effector/Central Memory T Cells versus Memory Stem Like T Cells. PLoS One (2013) 0.90
Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation. Ann N Y Acad Sci (2010) 0.86
Immunotherapy of melanoma. EJC Suppl (2013) 0.81
Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids. Eur J Dermatol (2015) 0.79
The immunologic treatment of cancer. CA Cancer J Clin (1988) 0.77
Prospective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patients. PLoS One (2014) 0.76